The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
3-((4-((2-methoxybenzo[d]thiazol-6-yl)amino)-5methylpyrimidin-2-yl)amino)benzenesulfonamide ID: ALA5203476
PubChem CID: 168293034
Max Phase: Preclinical
Molecular Formula: C19H18N6O3S2
Molecular Weight: 442.53
Associated Items:
Names and Identifiers Canonical SMILES: COc1nc2ccc(Nc3nc(Nc4cccc(S(N)(=O)=O)c4)ncc3C)cc2s1
Standard InChI: InChI=1S/C19H18N6O3S2/c1-11-10-21-18(23-12-4-3-5-14(8-12)30(20,26)27)25-17(11)22-13-6-7-15-16(9-13)29-19(24-15)28-2/h3-10H,1-2H3,(H2,20,26,27)(H2,21,22,23,25)
Standard InChI Key: NHMYKQBJKFHAAT-UHFFFAOYSA-N
Molfile:
RDKit 2D
30 33 0 0 0 0 0 0 0 0999 V2000
-5.1297 0.3462 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-4.3047 0.3462 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8338 -0.3074 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
-3.0296 -0.0572 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0296 0.7680 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8126 1.0139 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.3194 1.1798 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.6030 0.7717 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.6030 -0.0568 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3176 -0.4691 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8885 -0.4693 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.1738 -0.0568 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5433 -0.4710 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.2551 -0.0547 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9696 -0.4672 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.6840 -0.0547 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4016 -0.4689 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.1132 -0.0526 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.8278 -0.4650 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
4.4145 -1.1809 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.2394 -1.1809 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.5422 -0.0526 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.1132 0.7683 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3970 1.1809 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6840 0.7703 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2551 0.7662 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.5387 1.1788 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1738 0.7682 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8883 1.1807 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.5422 -0.3681 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 2 1 0
4 3 1 0
5 4 2 0
5 6 1 0
6 2 2 0
7 5 1 0
8 7 2 0
9 8 1 0
10 9 2 0
4 10 1 0
9 11 1 0
11 12 1 0
12 13 1 0
13 14 2 0
14 15 1 0
15 16 1 0
16 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
19 21 2 0
19 22 1 0
18 23 1 0
23 24 2 0
24 25 1 0
25 16 2 0
14 26 1 0
26 27 2 0
27 28 1 0
28 12 2 0
28 29 1 0
1 30 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 442.53Molecular Weight (Monoisotopic): 442.0882AlogP: 3.54#Rotatable Bonds: 6Polar Surface Area: 132.12Molecular Species: NEUTRALHBA: 9HBD: 3#RO5 Violations: ┄HBA (Lipinski): 9HBD (Lipinski): 4#RO5 Violations (Lipinski): ┄CX Acidic pKa: 10.24CX Basic pKa: 4.25CX LogP: 3.99CX LogD: 3.99Aromatic Rings: 4Heavy Atoms: 30QED Weighted: 0.41Np Likeness Score: -1.95
References 1. Chen Y, Li H, Yen R, Heckrodt TJ, McMurtrie D, Singh R, Taylor V, Masuda ES, Park G, Payan DG.. (2022) Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate., 13 (11.0): [PMID:36385926 ] [10.1021/acsmedchemlett.2c00411 ]